News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pulmatrix's PUR118 Demonstrates Potential to Reduce Acute Exacerbations of the Lung Associated with Progressive Respiratory Diseases, such as COPD, Asthma, CF, and Respiratory Infections



9/27/2011 9:55:38 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced today results from two preclinical studies demonstrating that PUR118, the company’s novel, inhaled dry-powder therapeutic, was effective in reducing airway inflammation and exacerbation response in animal models of progressive respiratory diseases. The results were presented during oral and poster sessions on September 26 and 27, 2011, at the European Respiratory Society (ERS) Annual Congress in Amsterdam, Netherlands.

Read at BioSpace.com


comments powered by Disqus
Pulmatrix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES